Keros Therapeutics Files 8-K on Security Holder Vote
Ticker: KROS · Form: 8-K · Filed: May 30, 2024 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | May 30, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
Related Tickers: KROS
TL;DR
Keros Therapeutics is having a shareholder vote soon, details to follow.
AI Summary
Keros Therapeutics, Inc. filed an 8-K on May 30, 2024, to report on the submission of matters to a vote of its security holders. The filing does not contain specific details about the matters to be voted on or any financial figures.
Why It Matters
This filing indicates that Keros Therapeutics is convening a meeting where shareholders will vote on important company matters, which could impact the company's future direction.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose new material financial or operational risks.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- May 30, 2024 (date) — Date of earliest event reported
FAQ
What specific matters will be submitted for a vote by Keros Therapeutics' security holders?
The filing states that matters are being submitted to a vote of security holders, but it does not specify what those matters are.
When is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is May 30, 2024.
What is the principal executive office address for Keros Therapeutics, Inc.?
The principal executive offices are located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
What is the SEC file number for Keros Therapeutics, Inc.?
The SEC file number for Keros Therapeutics, Inc. is 001-39264.
Under which section of the Securities Exchange Act of 1934 is this Current Report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 903 words · 4 min read · ~3 pages · Grade level 14.5 · Accepted 2024-05-30 16:01:43
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
Filing Documents
- kros-20240530.htm (8-K) — 50KB
- 0001664710-24-000045.txt ( ) — 175KB
- kros-20240530.xsd (EX-101.SCH) — 2KB
- kros-20240530_lab.xml (EX-101.LAB) — 22KB
- kros-20240530_pre.xml (EX-101.PRE) — 13KB
- kros-20240530_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On May 30, 2024, Keros Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), at which a quorum was present. At the Annual Meeting, the stockholders of the Company voted on the following four proposals: (1) to elect three nominees for director to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified ("Proposal 1"), (2) to ratify the selection by the Audit Committee of the Board of Directors of the Company (the "Board of Directors") of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024 ("Proposal 2"), (3) to approve, on an advisory basis, the compensation of the Company's named executive officers ("Proposal 3") as disclosed in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 17, 2024 (the "Proxy Statement") and (4) to indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers ("Proposal 4"). Each of Proposal 1, Proposal 2, Proposal 3 and Proposal 4 are described in detail in the Proxy Statement. The final results of the voting on each proposal are set forth below. Proposal 1 – Election of Directors The Company's stockholders elected the three persons listed below as directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The votes cast were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Jasbir Seehra, Ph.D. 28,980,411 199,924 3,109,658 Nima Farzan 22,751,167 6,429,168 3,109,658 Julius Knowles 21,464,815 7,715,520 3,109,658 Proposal 2 – Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the I
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: May 30, 2024